Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Hirokazu Shoji"'
Autor:
Chie Kudo-Saito, Hiroshi Imazeki, Hiroki Ozawa, Hirofumi Kawakubo, Hidekazu Hirano, Narikazu Boku, Ken Kato, Hirokazu Shoji
Publikováno v:
Translational Oncology, Vol 48, Iss , Pp 102075- (2024)
Peritoneal tumor dissemination and subsequent malignant tumor ascites (MTA) occur unexpectedly and repeatedly in patients with gastrointestinal (GI) cancers, and worsen quality of life and prognosis of the patients. Various treatments have been clini
Externí odkaz:
https://doaj.org/article/9a1d813fda324317aa1ac7ae97784b95
Autor:
Hiroki Osumi, Atsuo Takashima, Akira Ooki, Yuri Yoshinari, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Natsuko Okita, Ryoichi Sawada, Kota Ouchi, Koshiro Fukuda, Shota Fukuoka, Mariko Ogura, Daisuke Takahari, Keisho Chin, Hirokazu Shoji, Ken Kato, Naoki Ishizuka, Narikazu Boku, Kensei Yamaguchi, Eiji Shinozaki
Publikováno v:
Translational Oncology, Vol 35, Iss , Pp 101718- (2023)
Purpose: As circulating tumor DNA (ctDNA) measurement becomes more widespread, the “NeoRAS” phenomenon, where tissue rat sarcoma viral oncogene homolog (RAS) status converts from mutant (MT) to wild-type (WT) after treatment in metastatic colorec
Externí odkaz:
https://doaj.org/article/2dd4356f4b714e61ada692c8cdb096f1
Autor:
Yosui Nojima, Masahiko Aoki, Suyong Re, Hidekazu Hirano, Yuichi Abe, Ryohei Narumi, Satoshi Muraoka, Hirokazu Shoji, Kazufumi Honda, Takeshi Tomonaga, Kenji Mizuguchi, Narikazu Boku, Jun Adachi
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 21, Iss , Pp 2172-2187 (2023)
Apatinib is known to be a highly selective vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with anti-angiogenic and anti-tumor properties. In a phase III study, the objective response rate to apatinib was low. It remains unclear why
Externí odkaz:
https://doaj.org/article/96f2d6f634004bf692af38e6773e75d9
Autor:
Masahiko Aoki, Hirokazu Shoji, Kengo Nagashima, Hiroshi Imazeki, Takahiro Miyamoto, Hidekazu Hirano, Yoshitaka Honma, Satoru Iwasa, Natsuko Okita, Atsuo Takashima, Ken Kato, Kazuhide Higuchi, Narikazu Boku
Publikováno v:
ESMO Open, Vol 4, Iss 3 (2019)
Background Nivolumab showed a survival benefit for advanced gastric cancer (AGC). However, an acceleration of tumour growth during immunotherapy, (hyperprogressive disease, HPD) has been reported in various cancers. This study reviewed the HPD in pat
Externí odkaz:
https://doaj.org/article/3327d8c30dfd4cb790c56c4e235bb0ba